Table 7.
Results of prophylactic setting studies: subtype idiopathic angioedema
| Author | Year | Study design | Size | Disease duration (years) | Previous therapy | Therapy | Dosage scheme | Effect | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|
| Mansi [19] | 2014 | Cohort | 44 | n.r | n.r. | TA | 3 g/day → 0.5–3 mg/day | Reduction recurrences in 43 (98 %) | n.r. |
| Wintenberger [55] | 2014 | Cohort | 25 | n.r. | n.r. | TA | 2–2.5 g/day | Attack frequency from 15.2 (range = 2–50) to 3.7 (0–18) per 6 months. No response in 6 (24 %) | 6 |
| Firinu [56] | 2015 | Cohort | 16 | n.r. | AH + C | TA | 1.5–3 g/day | 50 % attack frequency decrease in 8 (50 %), no response in 5 (31 %), other in 3 | n.r. |
| Du-Thanh [58] | 2010 | CS | 25 | n.r. | AH + C | TA | 3 g/day | CR in 12 (48 %), PR in 11 (44 %), no response in 2 (8 %) | 20 |
| Cicardi [59] | 1999 | CS | 15 | Median 6 | AH | TA | 3 g/day | No further attacks in 8 (53 %), 7 attack frequency decreased by ≥75 % | 10–282 |
| Vela Vizcaino [48] | 2014 | CR | 1 | 3 | AH + C + E + C1INH | TA | 3 g/day | Attack frequency decrease from weekly to 3/8 weeks | n.r. |
| Saule [57] | 2012 | Cohort | 20 | n.r. | AH | Progestin | n.r. | Improvement in 19 (95 %) | 32,4 |
| Rijo Calderón [54] | 2013 | Cohort | 4 | n.r. | AH + C + dapsone | OMA | 150–300/2–4 | IR < 1 month | n.r. |
| Azofra [60] | 2015 | CS | 8 | n.r. | (AH + C +) TA | OMA | 300/4 | IR = 2–14 days | 6–12 m |
| Sands [61] | 2007 | CS-1 | 1 | 6 | AH + C + E + H2 | OMA | 300/3 | No further attacks | 24 |
| CS-2 | 1 | 4 | AH + C + H2 | OMA | 375/2 | No further attacks | 7 | ||
| CS-3 | 1 | 9 | AH + C + LTRA + H2 | OMA | 300/4 | 1 minor attack in 2 years | >12 | ||
| Büyüköztürk [64] | 2012 | CS-1 | 1 | 10 | AH + C + H+ O | OMA | 300/4 | CR within 4 months | n.r. |
| CS-2 | 1 | 15 | AH + C + H + IVIG + I | OMA | 300/4 | No further attacks | n.r. | ||
| von Websky [72] | 2013 | CR | 1 | n.r. | AH + C + LTRA + AB | OMA | 300/4 | CR = 2 days | 18 |
| Suna [73] | 2009 | CR | 1 | 19 | AH + C + H + IVIG + I | OMA | 300/2 | CR < 14 days | 4.5 |
| Stahl [43] | 2014 | CR | 1 | 1 | AH + C + E + H2 + TA + H + AB + LTRA + FFP + Ica | C1INH | 1000 U/ twice weekly | Attack frequency decrease 5–7/month to 1.5/month | n.r. |
| Bayer [74] | 2013 | CR | 1 | n.r. | AH + C + E + H2 + LTRA + H + I | C1INH | n.r. | Improvement after 2 doses of C1INH | n.r. |
| Perez [65] | 2010 | CS-1 | 1 | 2.75 | AH + C + I | MTX | 15/1 | IR = 28 days | n.r. |
Dosage scheme presented as milligrams administered every x weeks, unless stated otherwise. The effect of treatment is presented as initial response (IR), complete response (CR), and partial response (PR)
CS case series, CR case report, n.r. not reported, AH antihistamine, C corticosteroids, E epinephrine, C1-inh C1 inhibitor concentrate, TA tranexamic acid, H2 H2 antagonist, FFP fresh frozen plasma, P pantoprazole, LTRA leukotriene receptor antagonist, H hormones, AB antibiotics, I immunosuppressant, MTX methotrexate, H hydroxychloroquine, IVIG intravenous immunoglobulin, Ica icatibant, O others